Clinical trials recruiting for HR+/HER2- Breast Cancer
17
Recruiting trials
31
US states with sites
18
Countries
6%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 5 |
| Florida | 4 |
| Ohio | 4 |
| Texas | 4 |
| Virginia | 4 |
| Connecticut | 3 |
| New York | 3 |
| Oregon | 3 |
| Pennsylvania | 3 |
| Tennessee | 3 |
| Colorado | 2 |
| Iowa | 2 |
Top cities
Cleveland, Ohio 3Fairfax, Virginia 3New Haven, Connecticut 3San Antonio, Texas 3Sarasota, Florida 3Boston, Massachusetts 2Dallas, Texas 2Houston, Texas 2Los Angeles, California 2Nashville, Tennessee 2
Self-screener
Recruiting trials
- A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
- Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
- Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
- Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
- Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
- Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
- Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
- Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
- QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
- Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
- Study of AVZO-021 in Patients With Advanced Solid Tumors
Related conditions
Trials recruiting for HR+/HER2- Breast Cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Breast Neoplasms 105HR+, HER2-, Advanced Breast Cancer 4CDK4/6 Inhibitor 4Breast Diseases 8Triple Negative Breast Cancer (TNBC) 35TNBC - Triple-Negative Breast Cancer 35Primary Peritoneal Cancer 6Premenopausal Breast Cancer 5Metastatic Triple-Negative Breast Carcinoma 18
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for HR+/HER2- Breast Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.